• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

实现屏障损伤控制的最后一步。

The last step to achieve barrier damage control.

机构信息

Centro Malattie Apparato Digerente (CEMAD) Digestive Disease Center, Fondazione Policlinico Universitario "A. Gemelli" Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Università Cattolica del Sacro Cuore, Roma, Italy.

Unità Operativa Semplice Dipartimentale Day Hospital (UOSD DH) Medicina Interna e Malattie dell'ApparatoDigerente, Fondazione Policlinico Universitario "A. Gemelli" Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Università Cattolica del Sacro Cuore, Roma, Italy.

出版信息

Front Immunol. 2024 Feb 13;15:1354556. doi: 10.3389/fimmu.2024.1354556. eCollection 2024.

DOI:10.3389/fimmu.2024.1354556
PMID:38415254
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10897052/
Abstract

Heterogeneity characterises inflammatory diseases and different phenotypes and endotypes have been identified. Both innate and adaptive immunity contribute to the immunopathological mechanism of these diseases and barrier damage plays a prominent role triggering type 2 inflammation through the alarmins system, such as anti-Thymic Stromal Lymphopoietin (TSLP). Treatment with anti-TSLP monoclonal antibodies showed efficacy in severe asthma and clinical trials for other eosinophilic diseases are ongoing. The aim of this perspective review is to analyse current advances and future applications of TSLP inhibition to control barrier damage.

摘要

异质性是炎症性疾病的特征，已经确定了不同的表型和内型。先天免疫和适应性免疫都有助于这些疾病的免疫病理机制，屏障损伤通过警报素系统（如抗胸腺基质淋巴细胞生成素（TSLP））发挥突出作用，引发 2 型炎症。抗 TSLP 单克隆抗体治疗在严重哮喘中显示出疗效，针对其他嗜酸性粒细胞疾病的临床试验正在进行中。本观点综述的目的是分析 TSLP 抑制控制屏障损伤的当前进展和未来应用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ee87/10897052/e8dde149dddf/fimmu-15-1354556-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ee87/10897052/e8dde149dddf/fimmu-15-1354556-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ee87/10897052/e8dde149dddf/fimmu-15-1354556-g001.jpg

相似文献

1
The last step to achieve barrier damage control.实现屏障损伤控制的最后一步。
Front Immunol. 2024 Feb 13;15:1354556. doi: 10.3389/fimmu.2024.1354556. eCollection 2024.
2
Tezepelumab: an anti-thymic stromal lymphopoietin monoclonal antibody for the treatment of asthma.特泽布尔单抗：一种抗胸腺基质淋巴细胞生成素的单克隆抗体，用于治疗哮喘。
Immunotherapy. 2023 Dec;15(17):1435-1447. doi: 10.2217/imt-2023-0079. Epub 2023 Sep 19.
3
Thymic stromal lymphopoietin: its role and potential as a therapeutic target in asthma.胸腺基质淋巴细胞生成素：在哮喘中的作用及其作为治疗靶点的潜力。
Expert Opin Ther Targets. 2020 Aug;24(8):777-792. doi: 10.1080/14728222.2020.1783242. Epub 2020 Jun 27.
4
Thymic Stromal Lymphopoietin and Tezepelumab in Airway Diseases: From Physiological Role to Target Therapy.胸腺基质淋巴细胞生成素和特泽普单抗在气道疾病中的作用：从生理作用到靶向治疗。
Int J Mol Sci. 2024 May 29;25(11):5972. doi: 10.3390/ijms25115972.
5
Unmet need in severe, uncontrolled asthma: can anti-TSLP therapy with tezepelumab provide a valuable new treatment option?重度、未控制哮喘的未满足需求：特泽泊鲁单抗的抗 TSLP 疗法能否提供有价值的新治疗选择？
Respir Res. 2020 Oct 15;21(1):268. doi: 10.1186/s12931-020-01505-x.
6
Targeting interleukin-33 and thymic stromal lymphopoietin pathways for novel pulmonary therapeutics in asthma and COPD.针对白细胞介素-33 和胸腺基质淋巴细胞生成素通路的新型哮喘和 COPD 肺部治疗方法。
Eur Respir Rev. 2023 Jan 25;32(167). doi: 10.1183/16000617.0144-2022. Print 2023 Mar 31.
7
Current summary of clinical studies on anti-TSLP antibody, Tezepelumab, in asthma.抗TSLP抗体Tezepelumab治疗哮喘的临床研究现状总结。
Allergol Int. 2023 Jan;72(1):24-30. doi: 10.1016/j.alit.2022.11.006. Epub 2022 Dec 2.
8
Expression and Regulation of Thymic Stromal Lymphopoietin and Thymic Stromal Lymphopoietin Receptor Heterocomplex in the Innate-Adaptive Immunity of Pediatric Asthma.儿童哮喘固有-适应性免疫中的胸腺基质淋巴细胞生成素和胸腺基质淋巴细胞生成素受体异源复合物的表达和调节。
Int J Mol Sci. 2018 Apr 18;19(4):1231. doi: 10.3390/ijms19041231.
9
Thymic stromal lymphopoietin and alarmins as possible therapeutical targets for asthma.胸腺基质淋巴细胞生成素和警报素可能成为哮喘的治疗靶点。
Curr Opin Allergy Clin Immunol. 2021 Dec 1;21(6):590-596. doi: 10.1097/ACI.0000000000000793.
10
Tezepelumab for asthma.用于治疗哮喘的tezepelumab
Drugs Today (Barc). 2022 Dec;58(12):591-603. doi: 10.1358/dot.2022.58.12.3449205.

引用本文的文献

1
Thymic Stromal Lymphopoietin (TSLP): Evidence in Respiratory Epithelial-driven Diseases Including Chronic Rhinosinusitis with Nasal Polyps.胸腺基质淋巴细胞生成素（TSLP）：在包括伴鼻息肉的慢性鼻-鼻窦炎在内的呼吸道上皮驱动性疾病中的证据
Curr Allergy Asthma Rep. 2024 Dec 5;25(1):7. doi: 10.1007/s11882-024-01186-2.
2
The New Paradigm: The Role of Proteins and Triggers in the Evolution of Allergic Asthma.新范式：蛋白质和触发因素在过敏性哮喘演变中的作用。
Int J Mol Sci. 2024 May 25;25(11):5747. doi: 10.3390/ijms25115747.

本文引用的文献

1
Effect of Tezepelumab on Lung Function in Patients With Severe, Uncontrolled Asthma in the Phase 3 NAVIGATOR Study.在 3 期 NAVIGATOR 研究中，特泽泊单抗对重度、未控制哮喘患者肺功能的影响。
Adv Ther. 2023 Nov;40(11):4957-4971. doi: 10.1007/s12325-023-02659-y. Epub 2023 Sep 19.
2
Neuroimmune interplay during type 2 inflammation: Symptoms, mechanisms, and therapeutic targets in atopic diseases.2 型炎症期间的神经免疫相互作用：特应性疾病的症状、机制和治疗靶点。
J Allergy Clin Immunol. 2024 Apr;153(4):879-893. doi: 10.1016/j.jaci.2023.08.017. Epub 2023 Aug 25.
3
Biologic Therapies for Asthma and Allergic Disease: Past, Present, and Future.
哮喘与过敏性疾病的生物疗法：过去、现在与未来
Pharmaceuticals (Basel). 2023 Feb 10;16(2):270. doi: 10.3390/ph16020270.
4
The Role of TSLP in Atopic Dermatitis: From Pathogenetic Molecule to Therapeutical Target.TSLP 在特应性皮炎中的作用：从发病分子到治疗靶点。
Mediators Inflamm. 2023 Apr 15;2023:7697699. doi: 10.1155/2023/7697699. eCollection 2023.
5
Cytokine-targeted therapies for asthma and COPD.哮喘和 COPD 的细胞因子靶向治疗。
Eur Respir Rev. 2023 Apr 19;32(168). doi: 10.1183/16000617.0193-2022. Print 2023 Jun 30.
6
New Concepts in Barrier Dysfunction in CRSwNP and Emerging Roles of Tezepelumab and Dupilumab.慢性鼻-鼻窦炎伴鼻息肉中屏障功能障碍的新概念以及泰泽佩umab和度普利尤单抗的新作用
Am J Rhinol Allergy. 2023 Mar;37(2):193-197. doi: 10.1177/19458924231154061.
7
Long-term safety and efficacy of tezepelumab in people with severe, uncontrolled asthma (DESTINATION): a randomised, placebo-controlled extension study.特泽布尔单抗治疗严重、未控制哮喘患者的长期安全性和有效性（DESTINATION）：一项随机、安慰剂对照扩展研究。
Lancet Respir Med. 2023 May;11(5):425-438. doi: 10.1016/S2213-2600(22)00492-1. Epub 2023 Jan 23.
8
Expert consensus on the systemic treatment of atopic dermatitis in special populations.特应性皮炎特殊人群系统治疗专家共识。
J Eur Acad Dermatol Venereol. 2023 Jun;37(6):1135-1148. doi: 10.1111/jdv.18922. Epub 2023 Feb 8.
9
Novel insights into atopic dermatitis.特应性皮炎的新见解。
J Allergy Clin Immunol. 2023 May;151(5):1145-1154. doi: 10.1016/j.jaci.2022.10.023. Epub 2022 Nov 22.
10
Association between eosinophilic esophagitis and esophageal dysmotility: A systematic review and meta-analysis.嗜酸性食管炎与食管动力障碍之间的关联：一项系统评价与荟萃分析。
Neurogastroenterol Motil. 2023 Feb;35(2):e14475. doi: 10.1111/nmo.14475. Epub 2022 Sep 27.